Predictive Oncology announced it is partnering with Integra Therapeutics. The collaboration was created to pursue a novel method to enhance Integra Therapeutics' ability to use gene editing for future cancer therapies. Integra Therapeutics selected Predictive Oncology because of the company's protein expression experience and unique ability to optimize solubility and physical stability for expressed proteins.

Predictive Oncology uses a proprietary automated technology, called high-throughput self-interaction chromatography (HSC), to rapidly and accurately measure biomolecular interactions that assist pharmaceutical and biotech companies in drug development. This news comes on the heels of Predictive Oncology's release of a novel product designed for endotoxin removal and which involves a new high-capacity endotoxin column called EndoBind-R II. This highly specialized process and unique product design continually demonstrates superior performance and consistently delivers conclusive results.